Skip to main content

Johnson & Johnson said late Friday that a jury in Kentucky rejected claims that the company's baby powder contained asbestos and caused mesothelioma.

Shares of Johnson & Johnson (JNJ) rose 0.60% in Friday trade to close at $131.07.

Johnson & Johnson said this is the sixth case it has won in the past year on allegations that its baby powder caused mesothelioma and all verdicts against J&J have been overturned on appeal. The company faces thousands of lawsuits claiming its baby powder caused mesothelioma and ovarian cancer. The company has said concerns about talc's being linked to cancer are based on inconclusive research.

Scroll to Continue

TheStreet Recommends

In a statement, the company said, "Today's decision, and this trial track record, is consistent with the decades of clinical evidence and scientific studies by medical experts around the world that support the safety of Johnson's Baby Powder."

Asbestos, a carcinogen, sometimes appears in natural talc, but was stripped from commercial talc products in the 1970s, according to the American Cancer Society. Claims that talc used for feminine hygiene purposes can cause inflammation in the reproductive system are not supported by "the weight of evidence," according to the National Cancer Institute.

In a different legal case this week, the state of Oklahoma asked a judge to deliver a $17.2 billion verdict against the company, claiming the pharmaceutical industry, including Johnson & Johnson, flooded the state with opioids. Cleveland County District Judge Thad Balkman is expected to deliver his ruling later this month.

Johnson & Johnson is a holding in Jim Cramer'sAction Alerts PLUS Charitable Trust Portfolio. Want to be alerted before Cramer buys or sells these stocks? Learn more now.